Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Anticipates Flat Q4 Revenues

NEW YORK – Fluidigm reported on Tuesday that its preliminary fourth quarter revenues of 2019 are expected to be $32.0 to $32.4 million, which is at the upper end of the company’s guidance range of $29 to $32 million. In its year ago period, the firm posted revenues of $32.3 million.

On average, analysts expect the South-San Francisco-based company to report $30.2 million in revenues for Q4. During the recently completed quarter, it had mass cytometry annualized consumables pull-through of about $72,000. 

For full-year 2019, the company reported preliminary revenues of $116.7 to $117.2 million, which would be up about 3 percent to 4 percent from $113 million in 2018. The consensus Wall Street estimate is for $116.4 million in revenues.

Fluidigm said that its full-year mass cytometry revenue increased about 23 percent.  

Cash and cash equivalents, short-term investments, and restricted cash as of the end of 2019 were $60.7 million.  

The firm expects total fiscal year 2020 revenue to grow 8 to 11 percent year over year. 

Fluidigm's shares rose nearly 10 percent to $3.89 in morning trading on the Nasdaq.